{
    "clinical_study": {
        "@rank": "72159", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1 - Usual Brand Cigarette", 
                "arm_group_type": "Experimental", 
                "description": "smoking usual brand cigarette controls, who after 8-weeks will be offered Camel Snus and instructed for partial or complete substitution of cigarettes (subject's choice);"
            }, 
            {
                "arm_group_label": "Arm 2 - Complete Substitution", 
                "arm_group_type": "Experimental", 
                "description": "complete substitution (i.e., no smoking) and ad libitum use of snus;"
            }, 
            {
                "arm_group_label": "Arm 3 - Complete Substitution/Snus Use with Instructions", 
                "arm_group_type": "Experimental", 
                "description": "complete substitution (i.e., no smoking) and specific instructions for snus use based on the number of cigarettes smoked per day (if 10-20 cigarettes, use snus every 2 hours for about 8 pouches per day, and if >20 cigarettes then 12 pouches per day"
            }, 
            {
                "arm_group_label": "Arm 4 - Partial Substitution/Snus and Cigarettes", 
                "arm_group_type": "Experimental", 
                "description": "partial substitution with ad libitum use of both snus and cigarettes"
            }, 
            {
                "arm_group_label": "Arm 5 - Partial Substitution with Instructions", 
                "arm_group_type": "Experimental", 
                "description": "partial substitution with controlled use of snus (paralleling the instructions for complete substitution condition) and ad libitum smoking."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multi-center trial involving the University of Minnesota, Ohio State University\n      Comprehensive Cancer Center, and Roswell Park Cancer. Cigarette smokers who are eligible\n      will enter a Camel Snus sampling phase. Smokers interested in continuing with the study\n      after the sampling phase will undergo a 2 week baseline assessment phase and will then be\n      randomized to one of the five experimental conditions for 8 weeks. Tobacco use patterns,\n      subjective responses to product, and nicotine and toxicant exposure will be assessed."
        }, 
        "brief_title": "Methods Project 4: Clinical Trial", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Smoker", 
        "detailed_description": {
            "textblock": "Baseline smoking period: Subjects will be required to attend baseline clinic visits during\n      Week -2 and -1 of the clinical trial phase, and they will record their cigarette or other\n      tobacco intake on a daily basis using an interactive voice response system (IVR).\n\n      Experimental Period:  After the baseline assessment, subjects will be randomized to one of\n      five experimental conditions: 1) smoking usual brand cigarette controls, who after 8-weeks\n      will be offered Camel Snus to use as they will for 8 more weeks; 2) complete substitution\n      (i.e., no smoking) and ad libitum use of snus; 3) complete substitution (i.e., no smoking)\n      and specific instructions for snus use based on the number of cigarettes smoked per day (if\n      10-20 cigarettes, use snus every 2 hours for about 8 pouches per day, and if >20 cigarettes\n      then 12 pouches per day ; 4) partial substitution with ad libitum use of both snus and\n      cigarettes; and 5) partial substitution with controlled use of snus (paralleling the\n      instructions for complete substitution condition) and ad libitum smoking. Snus, but not\n      cigarettes, will be provided to subjects at the clinic visits."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female subjects who are at least 18 years of age;\n\n          -  smoking history of at least 10 cigarettes daily (Carbon Monoxide>8 or NicAlert >2)\n             for at least 1 year and no serious quit attempts in the last 3 months (to ensure\n             stability of smoking, particularly for those randomized to the continued smoking\n             group);\n\n          -  No unstable and significant medical or psychiatric conditions as determined by\n             medical history and Prime-MD questionnaire (to ensure safety of the subject, to\n             minimize the effects of poor health on biomarker measures and to maximize compliance\n             to study procedures);\n\n          -  Lack of stabilization of medications (determined by study MD);\n\n          -  Subject has provided written informed consent to participate in the study\n             (adolescents under the age of 18 will be excluded because this project involves\n             continued use of tobacco products and new tobacco products);\n\n        Exclusion Criteria:\n\n          -  Immune system disorders, respiratory diseases, kidney or liver diseases or any other\n             medical disorders that may affect biomarker data;\n\n          -  Current or recent alcohol or drug abuse problems (to ensure alcohol and drug use does\n             not affect biomarkers o nnf exposure and to maximize retention);\n\n          -  Regular tobacco use (e.g., greater than weekly or 9 times in last 30 days) other than\n             cigarettes;\n\n          -  Currently using nicotine replacement or other tobacco cessation products (to minimize\n             confounding effects of another product) or intention to quit in next three months;\n\n          -  Pregnant or breastfeeding (due to toxic effects from tobacco products).\n\n          -  Unable to read for comprehension or completion of study documents."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "793", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01867242", 
            "org_study_id": "2012NTLS050"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm 1 - Usual Brand Cigarette", 
                    "Arm 4 - Partial Substitution/Snus and Cigarettes", 
                    "Arm 5 - Partial Substitution with Instructions"
                ], 
                "description": "smoke their usual brand of cigarettes and follow their normal patterns", 
                "intervention_name": "Cigarettes", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Arm 1 - Usual Brand Cigarette", 
                    "Arm 2 - Complete Substitution", 
                    "Arm 3 - Complete Substitution/Snus Use with Instructions", 
                    "Arm 4 - Partial Substitution/Snus and Cigarettes", 
                    "Arm 5 - Partial Substitution with Instructions"
                ], 
                "description": "ad libitum - use as much or as little snus as they want", 
                "intervention_name": "Snus", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "cigarette", 
            "snus", 
            "smoking", 
            "tobacco"
        ], 
        "lastchanged_date": "May 29, 2013", 
        "location": [
            {
                "contact": {
                    "email": "hatsu001@umn.edu", 
                    "last_name": "Dorothy Hatsukami, M.D.", 
                    "phone": "612-626-2121"
                }, 
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55455"
                    }, 
                    "name": "Masonic Cancer Center, University of Minnesota"
                }, 
                "investigator": {
                    "last_name": "Dorothy Hatsukami, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Richard O'Connor, Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14263"
                    }, 
                    "name": "Roswell Park Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Richard O'Connor, Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Peter Shields, M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "Ohio State University Comprehensive Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Peter Shields, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "PROJECT 4: CLINICAL TRIAL METHODS FOR ASSESSING A TOBACCO PRODUCT Part of \"MODELS FOR TOBACCO PRODUCT EVALUATION", 
        "overall_contact": {
            "email": "hatsu002@umn.edu", 
            "last_name": "Dorothy Hatsukami, M.D.", 
            "phone": "612-626-2121"
        }, 
        "overall_contact_backup": {
            "email": "jense010@umn.edu", 
            "last_name": "Joni Jensen", 
            "phone": "612-624-5178"
        }, 
        "overall_official": {
            "affiliation": "Masonic Cancer Center, University of Minnesota", 
            "last_name": "Dorothy Hatsukami, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Rate of use of camel snus and use of cigarettes will be compared between groups.", 
            "measure": "Pattern of Tobacco Use", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01867242"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Carcinogen biomarkers (c-reactive protein and WBC) of exposure and effect and cardiovascular risk indicators were chosen because they have shown reasonable laboratory reproducibility, have clear differences in levels between smokers and nonsmokers and/or decrease upon tobacco cessation", 
                "measure": "Cardiovascular Biomarker Exposure", 
                "safety_issue": "No", 
                "time_frame": "4 months"
            }, 
            {
                "description": "Nicotine exposure and metabolite ratio (NMR) and the total nicotine equivalents will be determined.", 
                "measure": "Nicotine Biomarker Exposure", 
                "safety_issue": "No", 
                "time_frame": "4 months"
            }, 
            {
                "description": "Exhaled carbon monoxide (CO) and oxygen saturation as indicators of the extent to which red blood cells may be carrying their usual load of oxygen.", 
                "measure": "Carbon Monoxide Exposure", 
                "safety_issue": "No", 
                "time_frame": "4 months"
            }, 
            {
                "description": "Carcinogen biomarkers (NNAL, NNN, mercapturic acids) of exposure and effect were chosen because they have shown reasonable laboratory reproducibility, have clear differences in levels between smokers and nonsmokers and/or decrease upon tobacco cessation.", 
                "measure": "Carcinogen Biomarker of Exposure", 
                "safety_issue": "No", 
                "time_frame": "4 months"
            }
        ], 
        "source": "Masonic Cancer Center, University of Minnesota", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Masonic Cancer Center, University of Minnesota", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}